Borderline Tu

Question 1

Secondary tu in 173 pts with borderline ovarian tumors from Geneva Ca Registry?

Answer 1

Colorectal ca x 4;

Breast ca x 2, but p=0.0

• in <50yo

Question 2

LMP: Risk of recurrence ~ fertility preservation in French cohort of 360 pts from 2001:

Answer 2

Risk of recurrence with mean f/u of 37m:

Fertility preservation: 16%

at least BSO: 5%

Question 3

Serous LMP: systematic review of 4414 cases/42 studies: risk of lethal recurrence?

Data limited by relatively short f/u in studies.

Answer 3

Typical sBOT: 18%
Micropapillary patern: 17%
Non-invasive implants: 16%

Microinvasion: 11% - 2/3 baseline

Invasive implants: 34% - x2

Question 4

Mucinous LMP: systematic review of 894 mBOTs/12 studies: risk of lethal recurrence?

Data limited by relatively short f/u in studies.

Answer 4

Early stage mBOT and Intraepithelial carcinoma: 4%

No cases for 175😷with microinvasion and 6😷 with non-invasive implants

Question 5

Distribution of stage I ~ CA 125 of 50?

Upstaging per other study when LND was not required?

Answer 5

Stage I: 64 vs 35% for pts w/ preop CA -125 >50

15% are upstaged by 2nd procedure per other study

Question 6

Recurrence rate for sBOT ~ CA125 of 50?

Answer 6

DFS of 96 vs 85% for pts w/ CA125 >50 (at 5y)

Question 7

Recurrence of BOT ~ USO or less vs more extensive surgery

Answer 7

15 vs. 5% for not fertility sparing surgery

based on 360 French 💃🏻 from 2001

Question 8

Long term f/u of sBOT from Danish registry 1978-2002;
1026🚺; 15y median f/u:
Risk of serous carcinoma at 5 and 20 years for typical BOT (APST - atypical proliferative serous tumor) vs NI-LGSC (Non invasive LGSC, synonymous with micropapillary pattern)?

Answer 8

APST: 1 and 4% at 5 and 20y

NI-LGSC: 5 and 14%

Question 9

Long term f/u of sBOT from Danish registry 1978-2002;
1026🚺; 15y median f/u:
Risk factors for subsequent serous carcinoma at 5 and 20 years for typical BOT (APST - atypical proliferative serous tumor) (1-4%)?

Answer 9

34/946 ♻️🦠

Stage II+: HR-11
      Noninvasive: HR-11
      Invasive implants: HR-116
Bilateral: HR-8
Surface involvement: HR-5
Residual disease p surgery: HR-4

Question 10

Long term f/u of sBOT from Danish registry 1978-2002;
1026🚺; 15y median f/u:
Risk of ♻️ as APST for typical BOT (APST - atypical proliferative serous tumor) ~ surgical resection?

Answer 10

with BSO: 3% (22/752)

USO: 12% (20/164)

Cystectomy: 27% (8/30)

Question 11

Long term f/u of sBOT from Danish registry 1978-2002;
1026🚺; 15y median f/u:
Risk of serous carcinoma: timeframe?

Answer 11

Evenly distributed over 20 years for both APST and NI-LGSC

Question 12

Long term f/u of sBOT from Danish registry 1978-2002;
1026🚺; 15y median f/u:
Risk of serous carcinoma ~ type of tumor within implants?

Answer 12

No difference

NI-LGSC associated with ♻️ LGSC for s.I only: 5x APST